Windecker S, Pilgrim T.
doi.org/10.1016/S0140-6736(25)00441-6
Linked Article
ACURATE neo2 valve versus commercially available transcatheter heart valves in patients with severe aortic stenosis (ACURATE IDE): a multicentre, randomised, controlled, non-inferiority trial
Makkar et al. The Lancet, May 21, 2025
Transcatheter aortic valve implantation (TAVI) has transformed the treatment of aortic stenosis.1 A series of strategy trials comparing TAVI with surgical aortic valve replacement established TAVI as the mainstay treatment for older patients with aortic stenosis and catalysed the development of novel transcatheter heart valves (THVs).2,3 Distinct differences in valve design, release mechanism, and haemodynamic characteristics of various THVs have become the focus of recent investigations, marking the beginning of a new era of head-to-head THV comparisons.
